Literature DB >> 31570466

Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors.

Jhe-Cyuan Guo1,2,3, Chia-Chi Lin1,2, Chen-Yuan Lin4, Min-Shu Hsieh5, Hung-Yang Kuo1,6, Ming-Yu Lien4, Yu-Yun Shao1,3,6, Ta-Chen Huang7,6, Chih-Hung Hsu7,3,6.   

Abstract

BACKGROUND/AIM: This study explored the prognostic significance of the neutrophil-to-lymphocyte ratio (NLR) and use of antibiotics in advanced esophageal squamous cell carcinoma (ESCC) patients receiving immune checkpoint inhibitors (ICIs). PATIENTS AND METHODS: Patients were enrolled from two referral centers in Taiwan. Clinical benefit was defined as complete response, partial response, or a stable disease for ≥6 months via Response Evaluation Criteria In Solid Tumors 1.1. Clinicopathological factors' impact on overall survival (OS) and progression-free survival (PFS) was analyzed via Cox proportional hazards model.
RESULTS: Forty-nine patients were enrolled. The median PFS and OS were 1.8 and 6.1 months, respectively. The median NLR at baseline was 6.40, and 21 patients received antibiotics. Both high NLR and use of antibiotics were associated with inferior PFS (p=0.028 and p<0.001, respectively) and OS (p<0.001 and p<0.001, respectively) in multivariate analysis.
CONCLUSION: High NLR and use of antibiotics were associated with inferior survival in advanced ESCC patients receiving ICIs. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Antibiotic; esophageal squamous cell carcinoma; neutrophil–to–lymphocyte ratio; prognosis; programmed cell death protein-1

Mesh:

Substances:

Year:  2019        PMID: 31570466     DOI: 10.21873/anticanres.13765

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  Impact of Antiplatelet and Anticoagulant Therapies on Platelet-related Prognostic Markers in Patients With Esophageal Cancer.

Authors:  Yusuke Ishibashi; Hironori Tsujimoto; Keita Kouzu; Yujiro Itazaki; Satoshi Tsuchiya; Seiichiro Fujishima; Yoshihisa Yaguchi; Hidekazu Sugasawa; Shinsuke Nomura; Nozomi Ito; Manabu Harada; Hiromi Nagata; Eiji Shinto; Yoji Kishi; Hideki Ueno
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

Review 2.  Oral Microbiota Variation: A Risk Factor for Development and Poor Prognosis of Esophageal Cancer.

Authors:  Xiaobo Song; Ole K Greiner-Tollersrud; Huimin Zhou
Journal:  Dig Dis Sci       Date:  2021-09-09       Impact factor: 3.487

3.  The Impact of Lymphopenia and Dosimetric Parameters on Overall Survival of Esophageal Cancer Patients Treated with Definitive Radiotherapy.

Authors:  Ming Liu; Xiaoyang Li; Huaidong Cheng; Yansu Wang; Ye Tian
Journal:  Cancer Manag Res       Date:  2021-03-30       Impact factor: 3.989

Review 4.  Lymphopenia in Esophageal Cancer: What Have We Learned?

Authors:  Jia-Lin Wang; Rong Ma; Wei Kong; Ren Zhao; Yan-Yang Wang
Journal:  Front Oncol       Date:  2021-03-11       Impact factor: 6.244

5.  Is the survival of patients treated with ipilimumab affected by antibiotics? An analysis of 1585 patients from the French National hospital discharge summary database (PMSI).

Authors:  Pierre-Yves Cren; Nicolas Bertrand; Marie-Cécile Le Deley; Michaël Génin; Laurent Mortier; Pascal Odou; Nicolas Penel; Emmanuel Chazard
Journal:  Oncoimmunology       Date:  2020-11-22       Impact factor: 8.110

6.  Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2).

Authors:  Jianming Xu; Yi Li; Qingxia Fan; Yongqian Shu; Lei Yang; Tongjian Cui; Kangsheng Gu; Min Tao; Xiuwen Wang; Chengxu Cui; Nong Xu; Juxiang Xiao; Quanli Gao; Yunpeng Liu; Tao Zhang; Yuxian Bai; Wei Li; Yiping Zhang; Guanghai Dai; Dong Ma; Jingdong Zhang; Chunmei Bai; Yunchao Huang; Wangjun Liao; Lin Wu; Xi Chen; Yan Yang; Junye Wang; Shoujian Ji; Hui Zhou; Yan Wang; Zhuo Ma; Yanqi Wang; Bo Peng; Jiya Sun; Christoph Mancao
Journal:  Nat Commun       Date:  2022-02-14       Impact factor: 14.919

7.  Prognostic and predictive impact of neutrophil-to-lymphocyte ratio and HLA-I genotyping in advanced esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitor monotherapy.

Authors:  Lin Wang; Yanrong Zhu; Bo Zhang; Xi Wang; Hongnan Mo; Yuchen Jiao; Jiachen Xu; Jing Huang
Journal:  Thorac Cancer       Date:  2022-04-18       Impact factor: 3.223

8.  The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors.

Authors:  Jiaxin Zhou; Guowei Huang; Wan-Ching Wong; Da-Hai Hu; Jie-Wen Zhu; Ruiman Li; Hong Zhou
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

9.  Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis.

Authors:  Fausto Petrelli; Alessandro Iaculli; Diego Signorelli; Antonio Ghidini; Lorenzo Dottorini; Gianluca Perego; Michele Ghidini; Alberto Zaniboni; Stefania Gori; Alessandro Inno
Journal:  J Clin Med       Date:  2020-05-13       Impact factor: 4.241

10.  Prognostic value of immune-related genes in laryngeal squamous cell carcinoma.

Authors:  Weixing Liu; Chunyi Zhang; Xin Gong; Wenjing Liao; Jun Xu; Xiaowen Zhang
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.